Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.96
+0.14007.69%
Post-market: 1.95-0.0099-0.51%19:53 EDT
Volume:876.77K
Turnover:1.68M
Market Cap:44.42M
PE:-0.15
High:1.97
Open:1.85
Low:1.82
Close:1.82
52wk High:10.99
52wk Low:1.79
Shares:22.66M
Float Shares:17.07M
Volume Ratio:0.86
T/O Rate:5.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.13
PE(LYR):-0.11

Loading ...

Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives

Dow Jones
·
Jul 18

Karyopharm Grants 1,649 Rsus to Four New Hires Under Inducement Plan

Reuters
·
Jul 02

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Jun 17

Karyopharm posts Phase 3 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis

Reuters
·
Jun 14

Karyopharm posts endometrial cancer treatment landscape presentation

Reuters
·
Jun 09

Karyopharm joins Cantor-hosted webcast featuring endometrial cancer KOL Robert Coleman

Reuters
·
Jun 04

Karyopharm says Phase 3 SENTRY trial selected for presentation at EHA 2026

TIPRANKS
·
Jun 03

Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis

MT Newswires Live
·
Jun 02

Karyopharm’s selinexor combination shows efficacy in myelofibrosis

TIPRANKS
·
Jun 02

Karyopharm's Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at Eha 2026

THOMSON REUTERS
·
Jun 02

Karyopharm says Phase 3 SENTRY trial shows selinexor-ruxolitinib combo lifts SVR35 in myelofibrosis

Reuters
·
Jun 02

Karyopharm grants 1,200 RSUs to newly hired employee under inducement plan

Reuters
·
Jun 02

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 02

Karyopharm to discuss Phase 3 SENTRY trial results for selinexor plus ruxolitinib in myelofibrosis at June 2 call

Reuters
·
Jun 01

Karyopharm Therapeutics shareholders approve 3 million-share increase to 2022 equity plan at annual meeting

Reuters
·
May 29

Karyopharm management participates in Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

TIPRANKS
·
May 20

Karyopharm publishes corporate presentation highlighting selinexor Phase 3 trial readouts in 2026

Reuters
·
May 19

Karyopharm Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14